ZA200609427B - Quinazoline derivatives as erbB receptor tyrosine kinases - Google Patents

Quinazoline derivatives as erbB receptor tyrosine kinases

Info

Publication number
ZA200609427B
ZA200609427B ZA200609427A ZA200609427A ZA200609427B ZA 200609427 B ZA200609427 B ZA 200609427B ZA 200609427 A ZA200609427 A ZA 200609427A ZA 200609427 A ZA200609427 A ZA 200609427A ZA 200609427 B ZA200609427 B ZA 200609427B
Authority
ZA
South Africa
Prior art keywords
receptor tyrosine
tyrosine kinases
erbb receptor
quinazoline derivatives
quinazoline
Prior art date
Application number
ZA200609427A
Other languages
English (en)
Inventor
Bradbury Robert Hugh
Scott James Stewart
Kettle Jason Grant
Barlaam Bernard Christophe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200609427B publication Critical patent/ZA200609427B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200609427A 2004-06-04 2006-11-13 Quinazoline derivatives as erbB receptor tyrosine kinases ZA200609427B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04291393 2004-06-04

Publications (1)

Publication Number Publication Date
ZA200609427B true ZA200609427B (en) 2008-08-27

Family

ID=34969245

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200609427A ZA200609427B (en) 2004-06-04 2006-11-13 Quinazoline derivatives as erbB receptor tyrosine kinases

Country Status (16)

Country Link
US (1) US20070232607A1 (xx)
EP (1) EP1756088A1 (xx)
JP (1) JP2008501675A (xx)
KR (1) KR20070038500A (xx)
CN (1) CN1993349A (xx)
AR (1) AR049294A1 (xx)
AU (1) AU2005250224A1 (xx)
BR (1) BRPI0511741A (xx)
CA (1) CA2567832A1 (xx)
IL (1) IL179081A0 (xx)
MX (1) MXPA06014125A (xx)
NO (1) NO20066081L (xx)
TW (1) TW200602328A (xx)
UY (1) UY28940A1 (xx)
WO (1) WO2005118572A1 (xx)
ZA (1) ZA200609427B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
KR20050042055A (ko) * 2001-11-03 2005-05-04 아스트라제네카 아베 항종양제로서의 퀴나졸린 유도체
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
WO2005026151A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
AU2004272345A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
EP1667996B1 (en) * 2003-09-16 2009-07-22 Astrazeneca AB Quinazoline derivatives
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
CN1914182B (zh) * 2004-02-03 2011-09-07 阿斯利康(瑞典)有限公司 喹唑啉衍生物
ATE501148T1 (de) * 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
DE602006018331D1 (de) * 2005-09-20 2010-12-30 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
EP1940825A1 (en) * 2005-09-20 2008-07-09 Astra Zeneca AB Quinazoline derivatives as anticancer agents
CN101321739A (zh) * 2005-12-02 2008-12-10 阿斯利康(瑞典)有限公司 用作erbB酪氨酸激酶抑制剂的喹唑啉衍生物
JP2009517450A (ja) * 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ チロシンキナーゼ阻害薬としての４−アニリノ置換キナゾリン誘導体
PL2010528T3 (pl) 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
JP2010505811A (ja) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
KR20090089854A (ko) * 2006-10-12 2009-08-24 수퍼젠, 인크. Ｄｎａ 메틸화 조절을 위한 퀴놀린 유도체
CA2682504C (en) 2007-04-05 2012-10-30 Amgen Inc. Aurora kinase modulators and method of use
US7790746B2 (en) 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7939546B2 (en) 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US8404694B2 (en) 2008-03-20 2013-03-26 Amgen Inc. Aurora kinase modulators and method of use
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
CN105503836B (zh) * 2015-12-03 2018-04-24 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1502及其制备方法和应用
CN105503835B (zh) * 2015-12-03 2018-04-24 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1510及其制备方法和应用
CN105399733B (zh) * 2015-12-03 2018-04-24 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1504及其制备方法和应用
CN105541807B (zh) * 2015-12-03 2018-04-24 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1506及其制备方法和应用
CN106366020B (zh) * 2016-08-31 2018-12-11 京博农化科技股份有限公司 一种合成手性稻瘟酰胺的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE291897T1 (de) * 1996-01-31 2005-04-15 Cosmoferm Bv Verwendung von zusammensetzungen mit stabilisierten enzymen
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EE200100449A (et) * 1999-02-27 2002-12-16 Boehringer Ingelheim Pharma Kg 4-aminokinasoliini ja kinoliini derivaadid inhibeeriva toimega türosiinkinaaside vahendatud signaali ülekandele
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
KR20050042055A (ko) * 2001-11-03 2005-05-04 아스트라제네카 아베 항종양제로서의 퀴나졸린 유도체
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
UY28441A1 (es) * 2003-07-29 2005-02-28 Astrazeneca Ab Derivados de quinazolina
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
EP1667996B1 (en) * 2003-09-16 2009-07-22 Astrazeneca AB Quinazoline derivatives
WO2005026151A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
US20070037837A1 (en) * 2003-09-19 2007-02-15 Hennequin Laurent Francois A Quinazoline derivatives
JP2007506716A (ja) * 2003-09-25 2007-03-22 アストラゼネカ アクチボラグ キナゾリン誘導体
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
CN1914182B (zh) * 2004-02-03 2011-09-07 阿斯利康(瑞典)有限公司 喹唑啉衍生物

Also Published As

Publication number Publication date
UY28940A1 (es) 2006-01-31
IL179081A0 (en) 2007-03-08
MXPA06014125A (es) 2007-01-31
CN1993349A (zh) 2007-07-04
NO20066081L (no) 2007-02-20
TW200602328A (en) 2006-01-16
BRPI0511741A (pt) 2008-01-02
WO2005118572A1 (en) 2005-12-15
CA2567832A1 (en) 2005-12-15
US20070232607A1 (en) 2007-10-04
AU2005250224A1 (en) 2005-12-15
JP2008501675A (ja) 2008-01-24
AR049294A1 (es) 2006-07-12
EP1756088A1 (en) 2007-02-28
KR20070038500A (ko) 2007-04-10

Similar Documents

Publication Publication Date Title
IL179081A0 (en) QUINAZOLINE DERIVATIVES AS erbB RECEPTOR TYROSINE KINASES
HK1085400A1 (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
HK1091480A1 (en) Quinazoline derivatives as tyrosine kinase inhibitors
AP3433A (en) Triazolopyridazines as tyrosine kinase modultors
IL182094A0 (en) Quinazoline derivatives
HK1095590A1 (en) Quinazoline derivatives
TWI372751B (en) Pyrimidines as prostaglandin d2 receptor antagonists
IL180806A0 (en) Imidazopyrazine as tyrosine kinase inhibitors
IL207224A0 (en) Pyrrolo [2,3-d] pyrimidines and use thereof as tyrosine kinase inhibitors
PL1854789T3 (pl) Pochodna chinazoliny mająca aktywność hamowania kinazy tyrozynowej
HK1079195A1 (en) Quinazoline derivatives as src tyrosine kinase inhibitors
IL173483A0 (en) Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases
IL187895A0 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
GB0504018D0 (en) Quinazoline derivatives
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
HK1120793A1 (en) 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
SI1660090T1 (sl) Kinazolinski analogi kot inhibitorji receptorjev tirozin kinaze
ZA200710136B (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
GB0406160D0 (en) Quinazoline derivatives
GB0406163D0 (en) Quinazoline derivatives
GB0426653D0 (en) Quinazoline derivatives
IS8386A (is) Kínasólínafleiður sem týrósínkínasatálmar
GB0501614D0 (en) Quinazoline derivatives
GB0524001D0 (en) Quinazoline derivatives